WuXi Biologics (Cayman) Gelecekteki Büyüme

Future kriter kontrolleri 3/6

WuXi Biologics (Cayman) kazanç ve gelirin sırasıyla yıllık 17.6% ve 10.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 16.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 8.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

17.6%

Kazanç büyüme oranı

16.8%

EPS büyüme oranı

Life Sciences kazanç büyümesi	45.3%
Gelir büyüme oranı	10.6%
Gelecekteki özkaynak getirisi	8.9%
Analist kapsamı	Good
Son güncelleme	26 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

SHSC:2269 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	22,838	4,682	2,353	7,286	25
12/31/2025	20,136	3,948	1,074	6,261	27
12/31/2024	17,878	3,345	801	6,002	27
6/30/2024	17,116	2,632	-322	3,220	N/A
3/31/2024	17,075	3,016	145	3,944	N/A
12/31/2023	17,034	3,400	612	4,668	N/A
9/30/2023	16,794	3,776	N/A	N/A	N/A
6/30/2023	16,554	4,152	1,269	6,834	N/A
3/31/2023	15,911	4,286	471	6,188	N/A
12/31/2022	15,269	4,420	-327	5,542	N/A
9/30/2022	14,179	4,251	N/A	N/A	N/A
6/30/2022	13,090	4,081	-1,028	4,091	N/A
3/31/2022	11,690	3,735	-2,052	3,761	N/A
12/31/2021	10,290	3,388	-3,077	3,431	N/A
9/30/2021	9,183	3,092	-4,006	2,840	N/A
6/30/2021	8,075	2,795	-4,936	2,249	N/A
3/31/2021	6,844	2,242	-4,540	2,065	N/A
12/31/2020	5,612	1,689	-4,144	1,881	N/A
9/30/2020	4,967	1,494	-4,049	1,649	N/A
6/30/2020	4,321	1,300	-3,954	1,417	N/A
3/31/2020	4,152	1,157	-2,979	1,312	N/A
12/31/2019	3,984	1,014	-2,004	1,208	N/A
9/30/2019	3,535	922	-1,356	1,035	N/A
6/30/2019	3,087	831	-708	861	N/A
3/31/2019	2,811	731	-810	811	N/A
12/31/2018	2,534	631	-912	762	N/A
9/30/2018	2,277	520	-1,004	508	N/A
6/30/2018	2,019	410	-1,096	255	N/A
3/31/2018	1,819	331	N/A	308	N/A
12/31/2017	1,619	253	N/A	360	N/A
9/30/2017	1,429	177	N/A	320	N/A
6/30/2017	1,233	149	N/A	369	N/A
3/31/2017	1,111	145	N/A	226	N/A
12/31/2016	989	141	N/A	82	N/A
9/30/2016	889	171	N/A	162	N/A
12/31/2015	557	45	N/A	107	N/A
12/31/2014	332	42	N/A	22	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 2269 'nin tahmini kazanç büyümesi (yıllık 17.6% ) tasarruf oranının ( 2.3% ) üzerindedir.

Kazançlar ve Piyasa: 2269 şirketinin kazançlarının (yıllık 17.6% ) Hong Kong pazarından (yıllık 11.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 2269 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 2269 şirketinin gelirinin (yıllık 10.6% ) Hong Kong pazarından (yıllık 7.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 2269 şirketinin gelirinin (yıllık 10.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 2269 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 8.9 %).

WuXi Biologics (Cayman) Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

Investor sentiment deteriorates as stock falls 16%

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

Investor sentiment improves as stock rises 16%

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

CEO & Executive Director recently sold HK$6.6m worth of stock

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 18%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 19%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 28%

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Now 21% undervalued

Board Member recently sold HK$25m worth of stock

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Investor sentiment improves as stock rises 16%

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

CEO & Executive Director recently sold HK$4.6m worth of stock

Investor sentiment deteriorates as stock falls 20%

CEO & Executive Director recently sold HK$13m worth of stock

Now 21% undervalued after recent price drop

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Now 20% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021)

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

Now 21% undervalued

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

CEO & Executive Director recently sold HK$17m worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: CN¥0.81 (vs CN¥0.43 in FY 2020)

Less than half of directors are independent